BG105384A - CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH - Google Patents

CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH

Info

Publication number
BG105384A
BG105384A BG105384A BG10538401A BG105384A BG 105384 A BG105384 A BG 105384A BG 105384 A BG105384 A BG 105384A BG 10538401 A BG10538401 A BG 10538401A BG 105384 A BG105384 A BG 105384A
Authority
BG
Bulgaria
Prior art keywords
aze
cgl
pab
et02c
crystalline forms
Prior art date
Application number
BG105384A
Other languages
Bulgarian (bg)
English (en)
Inventor
Daniel Edvardsson
Lena Hedstroem
Anita Lundblad
Ursula Pettersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BG105384A publication Critical patent/BG105384A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
BG105384A 1998-09-03 2001-03-26 CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH BG105384A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802974A SE9802974D0 (sv) 1998-09-03 1998-09-03 New crystalline forms
PCT/SE1999/001514 WO2000014110A1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH

Publications (1)

Publication Number Publication Date
BG105384A true BG105384A (en) 2001-11-30

Family

ID=20412468

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105384A BG105384A (en) 1998-09-03 2001-03-26 CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH

Country Status (39)

Country Link
US (5) US6225287B1 (ru)
EP (1) EP1107980B1 (ru)
JP (2) JP3493341B2 (ru)
KR (1) KR100629825B1 (ru)
CN (1) CN1204143C (ru)
AP (1) AP1520A (ru)
AR (1) AR029312A1 (ru)
AT (1) ATE231521T1 (ru)
AU (1) AU763421B2 (ru)
BG (1) BG105384A (ru)
BR (1) BR9913464A (ru)
CA (1) CA2341259A1 (ru)
CU (1) CU23015A3 (ru)
CZ (1) CZ2001775A3 (ru)
DE (1) DE69905054T2 (ru)
DK (1) DK1107980T3 (ru)
EA (1) EA003264B1 (ru)
EE (1) EE200100135A (ru)
ES (1) ES2192101T3 (ru)
HK (1) HK1034721A1 (ru)
HR (1) HRP20010132B1 (ru)
HU (1) HUP0104330A2 (ru)
ID (1) ID28779A (ru)
IL (1) IL141433A0 (ru)
IS (1) IS1942B (ru)
MY (1) MY121394A (ru)
NO (1) NO20011083L (ru)
NZ (2) NZ510070A (ru)
OA (1) OA11908A (ru)
PL (1) PL346544A1 (ru)
SA (1) SA99200682B1 (ru)
SE (1) SE9802974D0 (ru)
SK (1) SK2802001A3 (ru)
TR (1) TR200100700T2 (ru)
TW (1) TWI247013B (ru)
UA (1) UA66869C2 (ru)
WO (1) WO2000014110A1 (ru)
YU (1) YU17301A (ru)
ZA (1) ZA200101763B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
JP4275407B2 (ja) * 2000-10-12 2009-06-10 中外製薬株式会社 新規な結晶構造を有するエリスロマイシン誘導体及びその製造方法
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
WO2003076391A2 (de) 2002-03-11 2003-09-18 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
WO2005031397A2 (en) * 2003-09-26 2005-04-07 Zetetic Institute Catoptric and catadioptric imaging systems with pellicle and aperture-array beam-splitters and non-adaptive and adaptive catoptric surfaces
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
WO2005091696A1 (fr) * 2004-03-29 2005-10-06 Quanta Display Inc. Structure a cadres pour module retroeclaire
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
ES2420989T3 (es) * 2010-02-26 2013-08-28 Biedermann Technologies Gmbh & Co. Kg Implante para estabilizar huesos o vértebras
US9550585B2 (en) 2014-06-09 2017-01-24 Space Systems/Loral, Llc Highly inclined elliptical orbit de-orbit techniques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1075277B (it) * 1977-02-11 1985-04-22 Erba Carlo Spa Derivati insaturi e epossidici dell'acio 7-acilamido-3-cefem-4-carbossilico e procedimento per la loro preparazione
US4315011A (en) * 1978-07-12 1982-02-09 Richter Gedeon Vegyeszeti Gyar Rt. 1-Alkyl-9-bromohexahydroindolo quinolizium salts and use thereof to increase blood flow
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
US5830805A (en) * 1996-11-18 1998-11-03 Cornell Research Foundation Electroless deposition equipment or apparatus and method of performing electroless deposition
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms

Also Published As

Publication number Publication date
AP2001002078A0 (en) 2001-03-31
CN1325406A (zh) 2001-12-05
DE69905054D1 (de) 2003-02-27
OA11908A (en) 2006-04-10
EE200100135A (et) 2002-06-17
HRP20010132B1 (en) 2004-06-30
HUP0104330A2 (hu) 2002-04-29
ID28779A (id) 2001-07-05
AU763421B2 (en) 2003-07-24
NO20011083D0 (no) 2001-03-02
WO2000014110A1 (en) 2000-03-16
JP2004075687A (ja) 2004-03-11
ATE231521T1 (de) 2003-02-15
CA2341259A1 (en) 2000-03-16
CN1204143C (zh) 2005-06-01
TWI247013B (en) 2006-01-11
UA66869C2 (ru) 2004-06-15
JP2002524467A (ja) 2002-08-06
TR200100700T2 (tr) 2001-07-23
CU23015A3 (es) 2005-01-25
US20050153901A1 (en) 2005-07-14
DE69905054T2 (de) 2003-11-06
SA99200682B1 (ar) 2006-08-22
US6440939B2 (en) 2002-08-27
US6888007B2 (en) 2005-05-03
IS1942B (is) 2004-08-13
NZ510070A (en) 2003-04-29
EA200100194A1 (ru) 2001-10-22
NZ524486A (en) 2004-10-29
BR9913464A (pt) 2001-06-12
DK1107980T3 (da) 2003-04-22
AR029312A1 (es) 2003-06-25
YU17301A (sh) 2004-05-12
ES2192101T3 (es) 2003-09-16
IS5870A (is) 2001-02-28
JP3493341B2 (ja) 2004-02-03
CZ2001775A3 (cs) 2001-10-17
SK2802001A3 (en) 2001-09-11
KR100629825B1 (ko) 2006-09-29
US20030017992A1 (en) 2003-01-23
US6225287B1 (en) 2001-05-01
HRP20010132A2 (en) 2002-02-28
EA003264B1 (ru) 2003-02-27
US20060287249A1 (en) 2006-12-21
MY121394A (en) 2006-01-28
AU6014799A (en) 2000-03-27
IL141433A0 (en) 2002-03-10
SE9802974D0 (sv) 1998-09-03
EP1107980B1 (en) 2003-01-22
PL346544A1 (en) 2002-02-11
AP1520A (en) 2005-12-28
US20050054579A9 (en) 2005-03-10
NO20011083L (no) 2001-05-03
US20010023244A1 (en) 2001-09-20
HK1034721A1 (en) 2001-11-02
KR20010088795A (ko) 2001-09-28
EP1107980A1 (en) 2001-06-20
ZA200101763B (en) 2002-06-03

Similar Documents

Publication Publication Date Title
BG105384A (en) CRYSTALLINE FORMS OF Et02C-CH2-(R)Cgl-Aze-Pab-OH
RS49688B (sr) Novi derivat 3-aril-2- hidroksipropionske kiseline (i)
EP0931788A3 (en) Metalloprotease inhibitors
RS49685B (sr) Novi oblik jedinjenja
AU2001232791A1 (en) Locking action holster
HK1036017A1 (en) Stable shaped particles of crystalline organic compounds.
AU4159297A (en) Neuropeptide-y ligands
CA2341291A1 (en) Pyridine ketones useful as herbicides
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU3992399A (en) Phase-comparator-less delay locked loop
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
MY122760A (en) Substantially crystalline form of melagatran
AU2002223084A1 (en) Nitrogen substituted 1,2,4-triazolo(3,4-a)phthalazine derivatives for enhancing cognition
AU1915399A (en) Cs-1 peptidomimetics, compositions and methods of using the same
MY128164A (en) Compounds
CA2317604A1 (en) Matrix metalloprotease inhibitors
CA2352392A1 (en) Eletriptan hydrobromide monohydrate
AU7027100A (en) Novel compounds
CA2309474A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
BG103017A (en) Liquid crystal compositions
CA2338276A1 (en) Fkbp inhibitors
AU2881399A (en) N1-modified glycopeptides
DE69837999D1 (en) Herbizide furanyl- und thienyloxyazine
CA2351819A1 (en) Fungicidal mixtures
AU4698399A (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors